Seasonal Allergies
Mauli B. Desai
Christina J. Yang
<div>
<div><span style="font-size: medium;"><span><span style="color: black;">Dr. Yang treats common pediatric otolaryngology problems including otitis media, obstructive sleep apnea, and tonsillitis. She underwent specialized fellowship training in the diagnosis and treatment of airway and swallowing disorders and also has a special interest in tracheostomy care and education.</span></span></span></div>
<div><span style="font-size: medium;"><span><span style="color: black;">Education:</span></span></span></div>
<div><span style="font-size: medium;"><span><span style="color: black;"><span>Clinical fellowship in Pediatric Otolaryngology: Cincinnati Children’s Hospital Medical Center</span></span></span></span></div>
<div> </div>
<div><span style="font-size: medium;"><span><span style="color: black;">R<span>esidency in Otolaryngology-Head and Neck Surgery: Tulane University School of Medicine </span></span></span></span></div>
<div><span style="font-size: medium;"><span><span style="color: black;">Medical School: Northwestern University Feinberg School of Medicine (</span></span></span><span style="font-size: medium;">Honors Program in Medical Education (HPME))</span></div>
<div><span style="font-size: medium;"><br /></span></div>
<div><span style="font-size: medium;">Dr. Yang has been on faculty at Albert Einstein College of Medicine / Montefiore Medical Center / the Children’s Hospital at Montefiore since 2015, focusing her efforts on quality improvement and multidisciplinary care for complex children including neonates and those with airway and swallowing issues. She is active in national societies including the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the American Society of Pediatric Otolaryngology (ASPO).</span></div>
<div><span style="font-size: medium;"><br /></span></div>
</div>
<div>
<div><span style="font-size: medium;"><span><span style="color: black;">Languages: English. Limited French and Mandarin Chinese.</span></span></span></div>
</div>
Dr. Yang’s clinical interests include airway and swallowing disorders in children, endoscopic and open airway reconstruction and tracheotomy.<quillbot-extension-portal></quillbot-extension-portal>
Dr. Yang’s research focuses on the application of healthcare simulation to medical education, patient safety, quality improvement and implementation science. <quillbot-extension-portal></quillbot-extension-portal>
<p>Christina J. Yang, MD, is Director, Pediatric Dysphagia Program; Associate Director, Pediatric Otolaryngology Quality Assurance and Assistant Professor at Montefiore-Einstein. Dr. Yang’s clinical interests include airway and swallowing disorders in children, endoscopic and open airway reconstruction and tracheotomy.</p><p>A graduate of Northwestern University, Dr. Yang received her Bachelor of Arts in 2004, and continued at the institution’s Feinberg School of Medicine, earning her Doctor of Medicine in 2008. She began her postdoctoral education at Tulane University School of Medicine, completing her residency in otolaryngology–head and neck surgery in 2013. She then pursued a fellowship in pediatric otolaryngology at Cincinnati Children’s Hospital Medical Center, completing it in 2015.</p><p>Dr. Yang’s research focuses on the application of healthcare simulation to medical education, patient safety, quality improvement and implementation science. Her work has been published in a number of journals and book chapters, and presented internationally. She is also a reviewer for the <em>International Journal of Pediatric Otorhinolaryngology, The Laryngoscope and the Journal of Otology</em>.</p><p>Dr. Yang is board certified by the American Board of Otolaryngology and a member of numerous professional societies, including the American Society of Pediatric Otolaryngology and the American Academy of Otolaryngology–Head and Neck Surgery.</p>
Danny Woo
Alanna M. Windsor
Daniel A. Weiser
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
Ivy Tam
Pediatric Medicine
Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children.
<p>Ivy Tam, MD, FAAP, is an Attending Physician and a Non-neonatal Emergency Transport Coordinator at Children’s Hospital at Montefiore. She is also an Assistant Professor of Pediatrics at our Albert Einstein College of Medicine. </p><p>In 2009, Dr. Tam received her Bachelor of Arts in Biological Sciences at Cornell University. She then attended SUNY Upstate Medical University, where she received her Doctor of Medicine in 2013. Dr. Tam began her postgraduate training with a residency in pediatrics at New York University School of Medicine, followed by a fellowship in pediatric hospital medicine in 2018 at the University of California San Diego. </p><p>Dr. Tam’s research aims to improve care and communication for patients with limited English proficiency, as well as standardizing pain practices for children. She has shared her work through presentations in academic forums and scientific meetings, and is currently in the process of being submitted for publication. </p><p>2017, Dr. Tam received the CARES Award from hospital staff at Rady Children’s Hospital for her support during the medical director’s absence. Dr. Tam is board certified by the American Board of Pediatrics and is a member of the American Academy of Pediatrics. </p>
Michele St. Louis
<p><span style="font-family: 'Times New Roman'; font-size: medium;">Michele St Louis received her MD from New York University School Of Medicine and completed her internship and residency in Family Medicine at Montefiore Medical Center. She completed fellowships in Developmental Disabilities and Faculty Development in the Department of Family Medicine at Montefiore. She is director of the Montefiore School Health Program and sees patients at the school-based health center in Theodore Roosevelt High School. Her clinical and research interests include health promotion and reproductive health care, including access to and satisfaction with long-acting reversible contraception (LARC) in adolescents. She is a Clinical Assistant Professor in Family Medicine.</span></p>
<p><strong>Education</strong></p>
<p>Undergraduate: Sophie Davis School of Biomedical Education, City College of New York, Bachelor’s Degree in Biomedical Science, Cum Laude<br />Medical School: New York University School of Medicine<br />Residency: Montefiore Medical Center (Family Medicine, Social Medicine)<br />Fellowships: Montefiore Medical Center (Developmental Disabilities Fellowship Program, Faculty Development Program)</p>
<p><strong>Professional Activity</strong></p>
<p>Dr. Michele St. Louis is Director of the Medical Division of the Montefiore School Health Program, and supervises residents and fellows in school-based health settings.</p>
<p>Her research focuses on teens' access to and acceptability of intrauterine devices in school-based health centers.</p>
<p>Patient Satisfaction with IUD Services in a School Based Health Center: A Pilot Study. Tara B Stein, MD, MPH, Aleza K Summit, MPH, Michele St Louis, MD, Marji Gold, MD Journal of Pediatric and Adolescent Gynecology, Vol 33, Issue 4, p 388-392 Jan 2020</p>
Jenny Shliozberg
<p>Jenny Shliozberg, MD, is an attending physician at the Children’s Hospital at Montefiore Einstein and Associate Professor, Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is in food allergy, hereditary angioedema (HAE), asthma, rhinitis, oral allergy syndrome and chronic urticaria. She frequently conducts food and drug challenges and has cared for HIV-positive and immunodeficient patients for the last 35 years.
</p><p>After earning her Doctor of Medicine at First Pavlov Medical University in St. Petersburg, Russia, Dr. Shliozberg continued with her postgraduate training at the same institution, completing her internship in obstetrics and gynecology followed by an ambulatory obstetrics and gynecology clinic. She later came to the United States, continuing her postgraduate training in 1984, completing a pediatric residency at Beth Israel Medical Center in 1987 and an allergy and immunology fellowship at Montefiore and Einstein in 1989.
</p><p>Dr. Shliozberg’s research focus includes food allergy, HAE, chronic sporadic urticaria, study in pediatric asthma, HIV and severe combined immunodeficiency and eosinophilic esophagitis. She is principal investigator on the use of Dupixent for pediatric patients, and has a study on AIR Supra use in children. Dr. Shilozberg has shared her work through peer-reviewed journals, book chapters, abstracts, posters and case reports and she has presented internationally and nationally. She has trained more than 70 fellows, many residents and medical students throughout her career.
</p><p>Dr. Shliozberg is board certified by the American Board of Allergy and Immunology. She is a Fellow of the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Dr. Shliozberg is a member of the American Association of Certified Allergists, the New York Allergy Society, and the Clinical Immunology Society.
</p>